Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05632926 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)
A Phase 2 study, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05632926 is a Phase 2 study that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 12 participants.
The verdict
NCT05632926, a Phase 2 study, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
Interventions
- DRUG 40 mg CBL-514
- DRUG 60 mg CBL-514
- DRUG 80 mg CBL-514
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05632926
The ClinicalTrials.gov registry entry for NCT05632926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 40 mg CBL-514 is the first listed.
NCT05632926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05632926 about?
NCT05632926 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)". The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
What is the current status of trial NCT05632926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-01-09. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT05632926?
The interventions under investigation include: 40 mg CBL-514 (DRUG), 60 mg CBL-514 (DRUG), 80 mg CBL-514 (DRUG).
Who is sponsoring clinical trial NCT05632926?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.